Palvella Therapeutics Inc., a clinical-stage biopharmaceutical company focused on rare skin diseases, announced the publication of a systematic review in Clinical and Experimental Dermatology synthesizing clinical evidence on off-label cutaneous statin use for porokeratosis. The review, which includes 24 studies, highlights persistent treatment gaps due to the lack of FDA-approved therapies for this condition and supports the development of Palvella's QTORIN™ pitavastatin for disseminated superficial actinic porokeratosis (DSAP). The company indicated that QTORIN™ pitavastatin is anticipated to enter Phase 2 clinical development in the second half of 2026. No new clinical study results have been presented; future trials are planned.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Palvella Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9646823-en) on February 02, 2026, and is solely responsible for the information contained therein.